GSK Buys Stiefel in $3.6 Billion Deal

April 20, 2009
Stiefel manufactures anti-itching creams, acne treatments and other skin care products.

British pharmaceutical giant GlaxoSmithKline said on April 20 that it has agreed to buy U.S.-based Stiefel Laboratories in a deal worth up to $3.6 billion dollars.

"GSK and Stiefel Laboratories today announced that they have signed an agreement to create a new world-leading specialist dermatology business," the pair said in a joint statement.

The deal for Stiefel, a maker of anti-itching creams, acne treatments and other skin care products, had been widely expected.

Copyright Agence France-Presse, 2009

About the Author

Agence France-Presse

Copyright Agence France-Presse, 2002-2024. AFP text, photos, graphics and logos shall not be reproduced, published, broadcast, rewritten for broadcast or publication or redistributed directly or indirectly in any medium. AFP shall not be held liable for any delays, inaccuracies, errors or omissions in any AFP content, or for any actions taken in consequence.

Sponsored Recommendations

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!